Bayer AG (ADR) (NASDAQOTH:BAYRY)

CAPS Rating: 3 out of 5

The Company offers products, including ethical pharmaceuticals and other health care products, agricultural products and polymers.

Results 1 - 20 of 31 : 1 2 Next »

Recs

0
Member Avatar nestorax (< 20) Submitted: 7/24/2014 9:27:48 PM : Outperform Start Price: $134.55 BAYRY Score: +1.50

Research improvement in treating patients with Diabetic Macular Edema

Recs

0
Member Avatar fritsd (70.85) Submitted: 6/24/2014 6:18:17 AM : Underperform Start Price: $142.13 BAYRY Score: +5.29

The bad news about neonicotinoids finally breaks through a critical barrier

Recs

0
Member Avatar chris293 (82.88) Submitted: 1/17/2014 11:10:16 PM : Outperform Start Price: $137.49 BAYRY Score: -8.03

Sometimes I compare BAYRY to JNJ or DOW for their products. And yet they are still, to me one of the best European companies. It just happens to be a German company that believes in science and the benefits of R & D as well as adding any companies that BAYRY feels will fit into their corporate structure.

Recs

1
Member Avatar wilkeh (41.51) Submitted: 6/6/2013 10:35:03 AM : Outperform Start Price: $104.89 BAYRY Score: +7.39

strong pharma business (Xarelto, Eylea, Stivarga, Xofigo and Riociguat) with peak sales potential of €5.5 billions. further improvements in CropScience, capacity additions in MaterialScience will be absorbed in market.

Recs

0
Member Avatar line70day (< 20) Submitted: 2/5/2013 11:09:12 AM : Outperform Start Price: $128.78 BAYRY Score: -3.53

Market Cap $80.2 B 52week range $59.57 - $102.54 nice rise in charts 1yr change +33.8 4 star

Recs

2
Member Avatar TRGoodvsEvil (79.57) Submitted: 7/3/2009 8:02:38 PM : Underperform Start Price: $47.97 BAYRY Score: -61.62

This portfolio tracks the performance of good vs. evil companies.

Evil attributes:
-4th largest toxic polluter in the world (http://www.peri.umass.edu/toxic100_index/)
-Inventor of mustard gas and heroin
-Nazi Fritz ter Meer became chairman of Bayer after having been sentenced at Nuremberg trials
-Supply antibiotics to livestock, creating dangerous antibiotic-resistant bacteria
-According to lawsuit, knowingly sold HIV-tainted blood products

Recs

1
Member Avatar jfontanot (< 20) Submitted: 10/18/2008 3:41:22 PM : Outperform Start Price: $49.33 BAYRY Score: +59.47

Panic has beaten this solid company with really good products.

Recs

0
Member Avatar halcyonsusan (< 20) Submitted: 7/1/2008 2:38:00 PM : Outperform Start Price: $77.04 BAYRY Score: +18.26

good portfolio of products and a well-run company

Recs

0
Member Avatar msncapsid (< 20) Submitted: 4/29/2008 11:34:05 AM : Outperform Start Price: $78.34 BAYRY Score: +26.93

health products, we will always need

Recs

0
Member Avatar wolfpack2003 (< 20) Submitted: 4/24/2008 9:20:57 AM : Outperform Start Price: $75.84 BAYRY Score: +31.27

ADR is a major provider in the agriculture industry. Ag is on the rise which should benefit ADR.

Recs

0
Member Avatar MsUsed (53.15) Submitted: 4/17/2008 11:48:54 AM : Outperform Start Price: $74.58 BAYRY Score: +33.59

Leading OTC pharmaceutical producer. Products are trusted and used widely and innovations are accepted.

Recs

0
Member Avatar MyPetersDragon (23.72) Submitted: 4/4/2008 11:58:14 PM : Outperform Start Price: $74.73 BAYRY Score: +32.98

Picked for their exposure to consumer fertilzers, a hot seller this spring

Recs

1
Member Avatar jjhoekstra (< 20) Submitted: 3/16/2008 2:06:33 PM : Underperform Start Price: $68.32 BAYRY Score: -41.08

The two top products (Betaseron and Yasmin) are now at risk from generics. They have some nice products in the oncology area, but no other usefull products in the research pipeline. The merger with Schering financially was a succes but former Schering personel is leaving the new company in droves. This is not good as the top products profit-wise are former Schering products.

Recs

0
Member Avatar klschmidt642 (< 20) Submitted: 1/5/2008 2:19:38 AM : Outperform Start Price: $82.69 BAYRY Score: +19.27

a standard in the pharmecutical field.

Recs

0
Member Avatar TrackMasterTrack (< 20) Submitted: 9/20/2007 5:17:05 AM : Outperform Start Price: $74.01 BAYRY Score: +49.09

should always beat he broad index, right?

Recs

0
Member Avatar fejaber (36.94) Submitted: 8/30/2007 9:41:40 AM : Outperform Start Price: $68.78 BAYRY Score: +56.12

if they brough us aspirin they will deliver much more in the years to come, fine german company, did i say german? yes i did.

Recs

0
Member Avatar NicieNicie (34.61) Submitted: 8/21/2007 5:25:11 PM : Outperform Start Price: $69.65 BAYRY Score: +53.88

Quality, quality, quality. These are ADR shares in German-headquartered BAYer, and as their product line diversifies -- it already is pretty global -- their chances to improve earnings look good.

Some stats are horrifying -- no P/E to speak of, share price running within a percent or two of 52-week high. I wouldn't put up with this from an American stock, but BAY seems to be digesting the old Schering-Plough well enough, and with that comes close-to-giant opportunities, in diversified scientific and health area. Bayer AG could, over time, become the next JNJ.

Recs

0
Member Avatar cruiser9806 (< 20) Submitted: 8/19/2007 5:41:22 PM : Outperform Start Price: $66.78 BAYRY Score: +61.56

Rthrombin is set to get approved in August. Once this comes out i expect it to bring up BAY value by 6% by itself over the next two to 4 years. Thats not counting the other drugs its got in its pipeline. Expect a 10-15% minimum annual growth over next 5 years.

Recs

0
Member Avatar McPicker (< 20) Submitted: 8/18/2007 8:47:14 PM : Outperform Start Price: $66.78 BAYRY Score: +61.56

Looking for a buyer and a breakup...

Recs

0
Member Avatar sixers33333 (60.65) Submitted: 8/7/2007 6:09:45 PM : Outperform Start Price: $67.22 BAYRY Score: +63.40

What the Market Is Missing: D'Amore believes the market is missing two factors that he thinks will drive Bayer's stock price higher. First, the company's prescription drug pipeline is in excellent shape. Nexavar for kidney cancer recently received FDA approval and is being tested for additional indications, including liver and skin cancer. Rivaroxaban, a promising new drug for hypertension, is in Phase III testing. The company also has eight other drugs in late-stage testing that are potentially significant revenue contributors. Second, D'Amore believes Bayer has excellent prospects for operating margin improvement. The company is capturing substantial operating leverage due to its decentralized operating structure and has been able to negotiate more flexible contracts with its labor unions than many European companies in the manufacturing sector. D'Amore thinks that Bayer will generate operating margins of 15% this year (up about 1 percentage point from 2006 after adjusting for nonrecurring items) and boost operating margins by another 4 percentage points by 2010.

Results 1 - 20 of 31 : 1 2 Next »

Featured Broker Partners


Advertisement